New drug acalabrutinib takes on standard combo in untreated CLL

NCT ID NCT04075292

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free survival). The goal is to see if acalabrutinib works better or has fewer side effects than the current standard therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acalabrutinib
What this could lead to: If successful, acalabrutinib could offer a more effective and possibly safer first-line treatment option for people with chronic lymphocytic leukemia.
What could go wrong: This is an early-stage Phase 3 trial with only 155 participants. Results may not apply to all patients, and acalabrutinib may have side effects or not prove superior to the standard combination therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Research Site

Beijing, 100191, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410013, China
Research Site

Changzhou, 272100, China
Research Site

Guangzhou, 510100, China
Research Site

Guangzhou, 510515, China
Research Site

Guiyang, 550004, China
Research Site

Hangzhou, 310003, China
Research Site

Hefei, 230001, China
Research Site

Hefei, 230031, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 210029, China
Research Site

Qingdao, 110016, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 200040, China
Research Site

Shanghai, 200050, China
Research Site

Shenyang, 110001, China
Research Site

Shijiazhuang, 050020, China
Research Site

Suzhou, 215006, China
Research Site

Taiyuan, 030001, China
Research Site

Tianjin, 300020, China
Research Site

Xuzhou, 221000, China
Research Site

Zhengzhou, 450008, China
Research Site

Zhengzhou, 450052, China
Research Site

Baguio City, 2600, Philippines
Research Site

Cebu, 6000, Philippines
Research Site

Davao City, 8000, Philippines
Research Site

Makati, 1229, Philippines
Research Site

Manila, 1000, Philippines
Research Site

Quezon City, 1112, Philippines
Research Site

Chiayi City, 613, Taiwan
Research Site

Hualien City, 97002, Taiwan
Research Site

Kaohsiung City, 833, Taiwan
Research Site

Taichung, 404, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10400, Thailand
Research Site

Bangkok, 10700, Thailand
Research Site

Chiang Mai, 50200, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Khon Kaen, 40002, Thailand
Research Site

Hanoi, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.